Precision BioSciences Inc (DTIL) is a Healthcare · Biotechnology company listed on NASDAQ. Price $6.64 (-0.45%), Market cap $0.19B, 52-week low–high $3.57 ~ $8.61.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the tre
Financial statements, price targets, institutional (13F) holdings and related news for Precision BioSciences Inc are updated in real time on BlackAll Trade.
Precision BioSciences Inc trades at $6.64 (-0.45%). Real-time quotes and charts are available on BlackAll Trade.
Precision BioSciences Inc has a market cap of about $0.19B.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. Th